Aldeyra Therapeutics, Inc.

NasdaqCM:ALDX Stock Report

Market Cap: US$105.6m

Aldeyra Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Todd Brady

Chief executive officer

US$4.7m

Total compensation

CEO salary percentage14.88%
CEO tenure14.3yrs
CEO ownership2.3%
Management average tenureno data
Board average tenure12.8yrs

Recent management updates

Recent updates

Analysis Article • Nov 27

Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Mar 05

Aldeyra Therapeutics Is Severely Undervalued Before PDUFA

Summary Aldeyra's reproxalap faced an FDA setback but showed positive trial results, leading to a resubmitted NDA with a PDUFA date of April 2025. Despite a controversial deal with AbbVie, Aldeyra remains financially solid, with $100M in cash and potential milestone payments. The DED market is strong, and reproxalap's data surpasses competitors, indicating significant undervaluation of Aldeyra's stock. With a market cap of $368M and promising assets, Aldeyra presents a compelling investment opportunity in the biotech sector. Read the full article on Seeking Alpha
Analysis Article • Feb 06

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Jun 21

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Analysis Article • Feb 16

Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Nov 06

Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Mar 26

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

CEO Compensation Analysis

How has Todd Brady's remuneration changed compared to Aldeyra Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$27m

Dec 31 2025US$5mUS$700k

-US$34m

Sep 30 2025n/an/a

-US$43m

Jun 30 2025n/an/a

-US$51m

Mar 31 2025n/an/a

-US$58m

Dec 31 2024US$4mUS$592k

-US$56m

Sep 30 2024n/an/a

-US$45m

Jun 30 2024n/an/a

-US$38m

Mar 31 2024n/an/a

-US$30m

Dec 31 2023US$4mUS$581k

-US$38m

Sep 30 2023n/an/a

-US$46m

Jun 30 2023n/an/a

-US$52m

Mar 31 2023n/an/a

-US$61m

Dec 31 2022US$3mUS$559k

-US$62m

Sep 30 2022n/an/a

-US$65m

Jun 30 2022n/an/a

-US$66m

Mar 31 2022n/an/a

-US$63m

Dec 31 2021US$3mUS$547k

-US$58m

Sep 30 2021n/an/a

-US$53m

Jun 30 2021n/an/a

-US$46m

Mar 31 2021n/an/a

-US$39m

Dec 31 2020US$2mUS$544k

-US$38m

Sep 30 2020n/an/a

-US$39m

Jun 30 2020n/an/a

-US$49m

Mar 31 2020n/an/a

-US$55m

Dec 31 2019US$4mUS$523k

-US$61m

Compensation vs Market: Todd's total compensation ($USD4.70M) is above average for companies of similar size in the US market ($USD631.70K).

Compensation vs Earnings: Todd's compensation has increased whilst the company is unprofitable.

CEO

Todd Brady (53 yo)

14.3yrs
Tenure
US$4,704,379
Compensation

Dr. Todd C. Brady, M.D., Ph D., served as a Director at F-star Therapeutics, Inc from November 20, 2020 to March 2023. He has been the Chief Executive Officer and President of Aldeyra Therapeutics, Inc. si...

Board Members

NamePositionTenureCompensationOwnership
Todd Brady
CEO, President & Director21.3yrsUS$4.70m2.34%
$ 2.5m
Richard Douglas
Independent Chair of the Board9.7yrsUS$225.22k0.32%
$ 341.2k
Ben Bronstein
Independent Director15.9yrsUS$192.72k0.047%
$ 49.4k
Gary Phillips
Independent Director17yrsUS$196.22k0.025%
$ 25.9k
Martin Joyce
Independent Director12.6yrsUS$197.72k0.040%
$ 41.9k
Neal Walker
Independent Director12.9yrsUS$177.47k0.026%
$ 27.7k
Jay Duker
Member of Retina Segment Scientific Advisory Boardno datano datano data
Paul Karpecki
Member of Anterior Segment Scientific Advisory Board6.3yrsno datano data
John Sheppard
Member of Anterior Segment Scientific Advisory Boardno datano datano data
Nancy Miller-Rich
Independent Director6.3yrsUS$177.47k0.0015%
$ 1.6k
Victor Perez
Member of Anterior Segment Scientific Advisory Boardno datano datano data
David Chu
Member of Anterior Segment Scientific Advisory Boardno datano datano data
12.8yrs
Average Tenure
66yo
Average Age

Experienced Board: ALDX's board of directors are seasoned and experienced ( 12.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/31 01:59
End of Day Share Price 2026/05/29 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aldeyra Therapeutics, Inc. is covered by 17 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Keay NakaeAscendiant Capital Markets LLC
Esther Lannie HongBerenberg
Douglas BuchananBrean Capital Historical (Janney Montgomery)